CANCER AND LEUKEMIA GROUP B
癌症和白血病 B 组
基本信息
- 批准号:6375474
- 负责人:
- 金额:$ 25.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1979
- 资助国家:美国
- 起止时间:1979-04-01 至 2003-03-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS related neoplasm /cancer aging antineoplastics bone marrow transplantation breast neoplasms cancer prevention cancer registry /resource carmustine chemoprevention cis platinum compound clinical research clinical trials combination cancer therapy combination chemotherapy cooperative study cyclophosphamide doxorubicin drug resistance finasteride fluorouracil gastrointestinal neoplasms health care cost /financing hormone therapy human genetic material tag human subject human therapy evaluation interleukin 2 leucovorin leukemia lymphoma melanoma neoplasm /cancer chemotherapy neoplasm /cancer diagnosis neoplasm /cancer epidemiology neoplasm /cancer genetics neoplasm /cancer immunotherapy neoplasm /cancer radiation therapy neoplasm /cancer surgery neoplasm /cancer vaccine oncology nursing paclitaxel pathology prostate neoplasms psychology quality of life respiratory neoplasm tamoxifen tissue resource /registry weight loss
项目摘要
DESCRIPTION (adapted from the applicant's abstract): The Comprehensive
Cancer Center of Wake Forest University continues to be a major accrue to
Cancer and Leukemia Group B protocols. A modest decrease in accrual is
noted for 1996 which reflects economic constraints and the influence of
managed care. We have obtained an R13 CA-74441 demonstration grant to
evaluate and strengthen the recruitment and retention of minorities in
cancer clinical trials. Further, we are applying through CALGB for the
minority initiative program to obtain data management support for East
Carolina University. They have access to a large minority population in
eastern North Carolina. The anticipation that first-line protocols for
leukemia, lymphoma, and advanced breast cancer will soon be available should
also strengthen our accrual in this grant period. Our institutional and
CCOP accrual to protocol #9399 (chemotherapy prevention of prostate cancer
with finasteride) is an expression of our ability to accrue large number of
patients quickly to cancer control clinical trials. Dr. David Hurd, Chair
of the Transplant committee and Dr. Electra Paskett, Chair of the Cancer
Control committee provide strong scientific contributions to CALGB and
further strengthen our accrual to clinical trials. Dr. Jim Atkins, Chairman
of the Southeast Cancer Control Consortium (SCCC), is developing a strong
regional program with increasing emphasis on the accrual of minorities to
clinical trials. Our strong community outreach clinical trials program is
focused to develop community techniques which will improve accrual to
clinical trials. The development of multi-disciplinary affinity groups in
breast, GI, GU, leukemia, lung, neuro-oncology, and oral head/neck cancer
will also strengthen our institutional contributions to Cancer and Leukemia
Group B.
描述(改编自申请人的摘要):综合
维克森林大学癌症中心继续成为
癌症和白血病B组方案。应计项目的小幅下降是
它反映了经济限制和
管理型医疗保健。我们已获得R13 CA-74441示范资助金
评估和加强少数民族的招募和留用工作
癌症临床试验。此外,我们正在通过CALGB申请
少数群体计划为EAST获得数据管理支持
卡罗莱纳大学。他们可以接触到大量的少数民族人口
北卡罗来纳州东部。预计第一线协议将用于
白血病、淋巴瘤和晚期乳腺癌很快就会出现
也加强我们在这一批款期的应计项目。我们的机构和
CCOP增加到9399号议定书(前列腺癌的化疗预防
使用非那雄胺)是我们有能力积累大量
患者迅速进行癌症控制临床试验。大卫·赫德博士,主席
移植委员会主席和癌症主席伊莱克拉·帕克特博士
控制委员会为CALGB和CALGB提供强大的科学贡献
进一步加强我们对临床试验的应计利润。吉姆·阿特金斯博士,主席
东南癌症控制联盟(SCCC)的成员,正在制定一项强大的
区域方案,日益重视少数群体的收益
临床试验。我们强大的社区外展临床试验计划是
专注于开发社区技术,以提高收益
临床试验。多学科亲和力群体在中国的发展
乳腺癌、胃肠道疾病、胃肠道疾病、白血病、肺癌、神经肿瘤学和口腔头颈癌
还将加强我们对癌症和白血病的机构贡献
B组。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID D HURD其他文献
DAVID D HURD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID D HURD', 18)}}的其他基金
CLINICAL TRIAL: SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)
临床试验:硒和维生素 E 预防癌症试验(选择)
- 批准号:
8167005 - 财政年份:2010
- 资助金额:
$ 25.98万 - 项目类别:
CLINICAL TRIAL: SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)
临床试验:硒和维生素 E 预防癌症试验(选择)
- 批准号:
7951366 - 财政年份:2009
- 资助金额:
$ 25.98万 - 项目类别:
SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)
硒和维生素 E 预防癌症试验(选择)
- 批准号:
7607668 - 财政年份:2007
- 资助金额:
$ 25.98万 - 项目类别:
DETECTION OF MDS USING FISH IN PRETRANSPLANT SAMPLES
使用移植前样本中的鱼检测 MDS
- 批准号:
6514402 - 财政年份:2001
- 资助金额:
$ 25.98万 - 项目类别:
DETECTION OF MDS USING FISH IN PRETRANSPLANT SAMPLES
使用移植前样本中的鱼检测 MDS
- 批准号:
6283617 - 财政年份:2001
- 资助金额:
$ 25.98万 - 项目类别:
相似海外基金
Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
- 批准号:
24K18114 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
- 批准号:
10089306 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Collaborative R&D
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
- 批准号:
498288 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Operating Grants
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
- 批准号:
498310 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Operating Grants
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
- 批准号:
23K20339 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
- 批准号:
2740736 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Studentship
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
- 批准号:
2305890 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Fellowship Award
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
- 批准号:
2406592 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Standard Grant
McGill-MOBILHUB: Mobilization Hub for Knowledge, Education, and Artificial Intelligence/Deep Learning on Brain Health and Cognitive Impairment in Aging.
McGill-MOBILHUB:脑健康和衰老认知障碍的知识、教育和人工智能/深度学习动员中心。
- 批准号:
498278 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Operating Grants
Welfare Enhancing Fiscal and Monetary Policies for Aging Societies
促进老龄化社会福利的财政和货币政策
- 批准号:
24K04938 - 财政年份:2024
- 资助金额:
$ 25.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)